Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

231 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The other colon cancer: a population-based cohort study of appendix tumour trends and prognosis.
Halfter K, Schubert-Fritschle G, Klauschen F, Werner J, Mayerle J, Weichert W, Friess H, Schmid R, Kremer M, Ruppert R, Hoelzl J, Krenz D, Nerlich A, Agha A, Fuchs M, Becker I, Nowak K, Engel J, Schlesinger-Raab A. Halfter K, et al. Among authors: klauschen f. Colorectal Dis. 2023 May;25(5):943-953. doi: 10.1111/codi.16510. Epub 2023 Feb 20. Colorectal Dis. 2023. PMID: 36748436
A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
Zhang D, Dorman K, Heinrich K, Weiss L, Boukovala M, Haas M, Greif PA, Ziemann F, Beyer G, Roessler D, Goni E, Renz B, D'Haese JG, Kunz WG, Seidensticker M, Corradini S, Niyazi M, Ormanns S, Kumbrink J, Jung A, Mock A, Rudelius M, Klauschen F, Werner J, Mayerle J, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Zhang D, et al. Among authors: klauschen f. Target Oncol. 2023 Sep;18(5):767-776. doi: 10.1007/s11523-023-00985-3. Epub 2023 Aug 18. Target Oncol. 2023. PMID: 37594677 Free PMC article.
Comparative transcriptomic analyses reveal activation of the epithelial-mesenchymal transition program in non-metastasizing low grade pseudomyxoma peritonei.
Pretzsch E, Neumann J, Nieß H, Pretzsch CM, Hofmann FO, Kirchner T, Klauschen F, Werner J, Angele M, Kumbrink J. Pretzsch E, et al. Among authors: klauschen f. Pathol Res Pract. 2024 Feb;254:155129. doi: 10.1016/j.prp.2024.155129. Epub 2024 Jan 14. Pathol Res Pract. 2024. PMID: 38232629 Free article.
Identification of a gene expression signature associated with brain metastasis in colorectal cancer.
Michl M, Taverna F, Woischke C, Li P, Klauschen F, Kirchner T, Heinemann V, von Bergwelt-Baildon M, Stahler A, Herold TM, Jurinovic V, Engel J, Kumbrink J, Neumann J. Michl M, et al. Among authors: klauschen f. Clin Transl Oncol. 2024 Aug;26(8):1886-1895. doi: 10.1007/s12094-024-03408-5. Epub 2024 Mar 17. Clin Transl Oncol. 2024. PMID: 38558282 Free PMC article.
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis.
Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, Pelusi N, Hartmann N, Rieke DT, Stephan-Falkenau S, Schuler M, Wermke M, Weichert W, Klauschen F, Haller F, Hummel HD, Sebastian M, Gattenlöhner S, Bokemeyer C, Esposito I, Jakobs F, von Kalle C, Büttner R, Wolf J, Hoffmann W. Kästner A, et al. Among authors: klauschen f. Lancet Reg Health Eur. 2023 Nov 22;36:100788. doi: 10.1016/j.lanepe.2023.100788. eCollection 2024 Jan. Lancet Reg Health Eur. 2023. PMID: 38034041 Free PMC article.
TIM-3 Qualifies as a Potential Immunotherapeutic Target in Specific Subsets of Patients with High-Risk Soft Tissue Sarcomas (HR-STS).
Berclaz LM, Altendorf-Hofmann A, Lindner LH, Burkhard-Meier A, Di Gioia D, Dürr HR, Klein A, Albertsmeier M, Schmidt-Hegemann NS, Klauschen F, Knösel T. Berclaz LM, et al. Among authors: klauschen f. Cancers (Basel). 2023 May 12;15(10):2735. doi: 10.3390/cancers15102735. Cancers (Basel). 2023. PMID: 37345075 Free PMC article.
Implementing precision oncology for sarcoma patients: the CCCLMUmolecular tumor board experience.
Berclaz LM, Burkhard-Meier A, Lange P, Di Gioia D, Schmidt M, Knösel T, Klauschen F, von Bergwelt-Baildon M, Heinemann V, Greif PA, Westphalen CB, Heinrich K, Lindner LH. Berclaz LM, et al. Among authors: klauschen f. J Cancer Res Clin Oncol. 2023 Nov;149(15):13973-13983. doi: 10.1007/s00432-023-05179-y. Epub 2023 Aug 5. J Cancer Res Clin Oncol. 2023. PMID: 37542550 Free PMC article.
Patient eligibility for trials with imaging response assessment at the time of molecular tumor board presentation.
Mansour N, Heinrich K, Zhang D, Winkelmann M, Ingenerf M, Gold L, Klambauer K, Rudelius M, Klauschen F, von Bergwelt-Baildon M, Ricke J, Heinemann V, Westphalen CB, Kunz WG. Mansour N, et al. Among authors: klauschen f. Cancer Imaging. 2024 Jun 7;24(1):70. doi: 10.1186/s40644-024-00708-5. Cancer Imaging. 2024. PMID: 38849902 Free PMC article.
231 results